... (Bottom) of Cases of MRSA Infection among St. Louis Ram - PowerPoint PPT Presentation

1 / 14
About This Presentation
Title:

... (Bottom) of Cases of MRSA Infection among St. Louis Ram

Description:

... (Bottom) of Cases of MRSA Infection among St. Louis Rams Football Players in 2003 ... Scottish, Irish. TNFR. type 1. TNFRSF1A. 12p13. AD. Jewish, Turkish, ... – PowerPoint PPT presentation

Number of Views:47857
Avg rating:3.0/5.0
Slides: 15
Provided by: S369
Category:

less

Transcript and Presenter's Notes

Title: ... (Bottom) of Cases of MRSA Infection among St. Louis Ram


1
Epidemic-Curve Graph (Top) and Field Position
Diagram (Bottom) of Cases of MRSA Infection among
St. Louis Rams Football Players in 2003
2
The New Campaign
3
The New Campaign
4
The Otx Sales Process
1. Meeting an unmet need
2. Cahiers Des Charges
3. Product Development
4. Marketing
Brand Plan
Outcome Driven
5
Familial Periodic Fever Syndromes
6
Distribution of Child Care US
Data from Childrens Defense Fund. CDF
Publications 1998
CCC Child care center CCH Family CCC
7
Rare Tlr 4 Mutations Are AssociatedWith
Meningococcal Susceptibility
Smirnova I, et al. Proc Natl Acad Sci USA.
20031006075-6080.
8
West Nile Virus (WNV)
http//www.dierentuin.net/pictures/huismuis.jpg
anatomy.ucsf.edu/Pages/mouseclub/mousejournalclub.
html
wildlife.usask.ca/WestNileAlertHTML/viron.jpg
9
A stop codon in exon 4 of the interferon
response gene, 2-5-oligoadenylate synthetase/L1
isoform (Oas1) may be responsible for
susceptibility to WNV and other flaviviruses
Perelygin AA, et al. Proc Natl Acad Sci USA.
2002999322-9327. Mashimo T, et al. Proc Natl
Acad Sci USA. 20029911311-11316.
10
Relevance to Humans?
  • 20 symptomatic
  • 1/150 with meningitis or encephalitis
  • 20 symptomatic
  • 1/150 with meningitis or encephalitis

WNV
11
Men B Vaccine A Genomic Approach
600 potential vaccine candidates identified
350 proteins expressed in E. coli 344 proteins
used to immunize mice 355 sera tested 91
novel surface-exposedproteins identified 29
novel proteins induce bactericidal activity
18 months
24 months
Scale-up GMP / IND 1 year
5 vaccine candidates
Clinical trial
12
Alefacept in Psoriasis
Phase 3 Efficacy Results
Weeks 112 Dosing
Weeks 1324 Follow-up
Placebo
Alefacept 7.5 mg
Weeks
2
4
6
8
10
12
14
16
18
20
22
24
Krueger GG, et al. J Amer Acad Dermatol.
200247821-833 Lebwohl M, et al. Arch
Dermatol. 2003139719-727.
13
Linezolid for MRSA pneumonia?
  • Clinical cure rates for linezolid and vancomycin
    therapy
  • in patients with Gram-positive, nosocomial
    pneumonia

Wunderink, R. G. et al. Chest 20031241789-1797
14
Mechanism of Action
Domain V
Domain II
Site of methylation
Telithromycin binds 10X more strongly than
macrolides because of its better domain II
contact
Binding sites for both macrolides telithromycin
Douthwait et al Mol Micro 36183, 2000
Write a Comment
User Comments (0)
About PowerShow.com